Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors, has revolutionized the systematic treatment of advanced and metastatic solid tumors. However, the response rate to ICIs is unsatisfactory, a...

Full description

Bibliographic Details
Main Authors: Dongfeng Feng, Yaping Guan, Mingguo Liu, Shuqian He, Weipeng Zhao, Beibei Yin, Jing Liang, Yan Li, Jun Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
hyperprogressive disease
immune checkpoint inhibitor
pembrolizumab
atezolizumab
triple-negative breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.608292/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.608292/full

Similar Items